​

Kala Pharmaceuticals (KALA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

KALA Stock Forecast

Kala Pharmaceuticals (KALA) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $7.50, with a high of $7.50 and a low of $7.50. This represents a 116.76% increase from the last price of $3.46.

$3 $4 $5 $6 $7 $8 High: $7.5 Avg: $7.5 Low: $7.5 Last Closed Price: $3.46

KALA Stock Rating

Kala Pharmaceuticals stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (66.67%), 2 Hold (22.22%), 1 Sell (11.11%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 1 2 6 Strong Sell Sell Hold Buy Strong Buy

KALA Price Target Upside V Benchmarks

TypeNameUpside
StockKala Pharmaceuticals116.76%
SectorHealthcare Stocks 35.94%
IndustrySpecialty & Generic Drug Manufacturers Stocks45.40%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$8.25
Last Closing Price$3.46$3.46$3.46
Upside/Downside--138.44%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2511---2
Mar, 2511---2
Feb, 2511---2
Jan, 2511---2
Dec, 2411---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 07, 2024Yi ChenH.C. Wainwright$7.50$3.10141.94%116.76%
May 17, 2024Yi ChenH.C. Wainwright$9.00$3.25176.92%160.12%
Apr 03, 2024Yi ChenH.C. Wainwright$10.50$4.00162.50%203.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 18, 2024H.C. WainwrightBuyBuyhold
Aug 19, 2024OppenheimerOutperformOutperformhold
Aug 07, 2024H.C. WainwrightBuyBuyhold
May 17, 2024H.C. WainwrightBuyBuyhold
Apr 03, 2024H.C. WainwrightBuyBuyhold
Dec 29, 2022WedbushOutperformOutperformhold
Aug 15, 2022Piper SandlerBuyBuyhold
Apr 25, 2022Zacks Investment ResearchHoldupgrade

Financial Forecast

EPS Forecast

$-150 $-120 $-90 $-60 $-30 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-106.92$-116.79$-0.15$-17.35$-1.01---
Avg Forecast$-92.29$-87.90$-23.79$-18.03$-10.84$-6.22$-4.28$-9.31
High Forecast$-92.29$-87.90$-23.79$-17.25$-10.60$-6.02$-4.28$-9.31
Low Forecast$-92.29$-87.90$-23.79$-18.54$-11.06$-6.40$-4.28$-9.31
Surprise %15.85%32.87%-99.37%-3.77%-90.68%---

Revenue Forecast

$0 $9M $18M $27M $36M $45M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$6.36M$11.24M$3.89M-----
Avg Forecast$6.43M$12.58M$3.76M$1.67M$3.33M$41.35M$25.00M$26.12M
High Forecast$6.43M$12.58M$3.76M$1.67M$3.33M$41.35M$25.00M$26.12M
Low Forecast$6.43M$12.58M$3.76M$1.67M$3.33M$41.35M$25.00M$26.12M
Surprise %-1.02%-10.68%3.47%-----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-112.00M$-152.30M$-223.00K$-42.20M$-38.51M---
Avg Forecast$-92.57M$-213.77M$-109.14M$-42.20M$-26.34M$-15.10M$-10.41M$-22.64M
High Forecast$-74.05M$-213.77M$-87.31M$-33.76M$-25.77M$-14.63M$-10.41M$-22.64M
Low Forecast$-111.08M$-213.77M$-130.97M$-50.64M$-26.91M$-15.58M$-10.41M$-22.64M
Surprise %21.00%-28.76%-99.80%-46.21%---

KALA Forecast FAQ

Is Kala Pharmaceuticals stock a buy?

Kala Pharmaceuticals stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Kala Pharmaceuticals is a favorable investment for most analysts.

What is Kala Pharmaceuticals's price target?

Kala Pharmaceuticals's price target, set by 9 Wall Street analysts, averages $7.5 over the next 12 months. The price target range spans from $7.5 at the low end to $7.5 at the high end, suggesting a potential 116.76% change from the previous closing price of $3.46.

How does Kala Pharmaceuticals stock forecast compare to its benchmarks?

Kala Pharmaceuticals's stock forecast shows a 116.76% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the specialty & generic drug manufacturers stocks industry (45.40%).

What is the breakdown of analyst ratings for Kala Pharmaceuticals over the past three months?

  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Kala Pharmaceuticals’s EPS forecast?

Kala Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-6.22, marking a 515.84% increase from the reported $-1.01 in 2024. Estimates for the following years are $-4.28 in 2026, and $-9.31 in 2027.

What is Kala Pharmaceuticals’s revenue forecast?

Kala Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $41.35M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $25M, and $26.12M for 2027.

What is Kala Pharmaceuticals’s net income forecast?

Kala Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-15.103M, representing a -60.78% decrease from the reported $-38.511M in 2024. Projections indicate $-10.409M in 2026, and $-22.642M in 2027.